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Traumatic brain injury (TBI) triggers multiple pathobiological responses with differing 
onsets, magnitudes, and durations. Identifying the therapeutic window of individual 
pathologies is critical for successful pharmacological treatment. Dozens of experimental 
pharmacotherapies have been successfully tested in rodent models, yet all of them (to 
date) have failed in clinical trials. The differing timescales of rodent and human biological 
and pathological processes may have contributed to these failures. We compared rodent 
versus human timescales of TBI-induced changes in cerebral glucose metabolism, 
inflammatory processes, axonal integrity, and water homeostasis based on published data. 
We found that the trajectories of these pathologies run on different timescales in the two 
species, and it appears that there is no universal “conversion rate” between rodent and 
human pathophysiological processes. For example, the inflammatory process appears to 
have an abbreviated timescale in rodents versus humans relative to cerebral glucose 
metabolism or axonal pathologies. Limitations toward determining conversion rates for 
various pathobiological processes include the use of differing outcome measures in 
experimental and clinical TBI studies and the rarity of longitudinal studies. In order to 
better translate time and to close the translational gap we suggest a) using clinically 
relevant outcome measures, primarily in vivo imaging and blood-based proteomics, in 
experimental TBI studies and b) collecting data at multiple post-injury time points with a 
frequency exceeding the expected information content by two or three times. Combined 
with a big data approach, we believe these measures will facilitate the translation of 
promising experimental treatments into clinical use.  















































































































































































































































































GENERAL INTRODUCTION  
The latest Phase 3 clinical trials of progesterone, ProTECT and SyNAPSe, are the newest 
contribution to the 100% rate of failure in translating experimentally efficacious 
pharmacotherapies for traumatic brain injury (TBI) into clinical use.1, 2 Factors that have 
potentially contributed to this failure, including heterogeneity of the patient population, 
varying treatment paradigms, dosing, and poorly defined outcome measures, have been 
widely discussed elsewhere,3, 4 with broader discussions about the challenges facing 
successful translation of experimental TBI pharmacotherapies into clinical use.4-7 Rodent 
models of human diseases are the backbone of modern biomedical research. However, a 
limited understanding of inter-species differences, including the differing timescales of 
rodent and human pathological processes, can significantly hinder the translation of 
diseases with dynamically changing molecular pathologies like TBI. The limitations of 
modeling complex CNS disorders in animals, especially in rodents, have been extensively 
discussed.8-10 High-fidelity modeling of TBI in rodents is particularly challenging due to the 
complexities of physical-biological coupling, i.e., how physical forces impacting the head 
translate first into biomechanical forces then biological responses.11 The differences 
between human and rodent heads and brains in terms of size, gross anatomies, and 
cytoarchitectures have also been discussed.12, 13 Importantly, there is substantial variation 
in the temporal pattern of normal biological processes, such as gestation, sexual 
maturation, and lifespan.14 Analysis of the available literature has shown that a “rat hour” 
or “rat day” is not equivalent to a “human hour” or “human day” (and vice versa), but 
there seems to be no generally applicable conversion factor. Our limited understanding of 
the temporal differences in rodents’ and humans’ pathobiological response to injury can 
be attributed to two main factors: the use of different outcome measures in experimental 
versus clinical TBI studies, and the limited number of longitudinal studies with sufficient 
sampling frequency. The dominance of post-mortem outcome measures (e.g., histology) in 
experimental TBI research, at the expense of more clinically relevant measures (e.g., 















































































































































































































































































Furthermore, most experimental and clinical TBI studies use single time points, largely 
focused on the acute phase of the injury. This, too, is a major limiting factor as both the 
identity and the intensity of the pathobiological process can substantially change over 
time.15  
In this review, we compare the rat and human timescales of (a) cerebral glucose 
metabolism, (b) inflammation, (c) vascular permeability / water imbalance, and (d) axonal 
changes following TBI. We have summarized our findings graphically (Fig. 1-4) based on 
available literature. We selected data based on identical and/or as comparable as possible 
methodologies used both in experimental and in clinical TBI studies. As discussed below, 
the differences in outcome measures used in clinical vs. experimental studies majorly 
affect translatability between the two fields. The quantity of literature data regarding the 
timelines of these four TBI-related pathobiological processes varies substantially, as 
reflected in the length and details of the relevant discussions. Our comparison is limited to 
studies with identical or comparable outcome measures in experimental and clinical TBI. 
While published literature on stroke, spinal cord injury, and peripheral nerve injury may 
provide information that is currently unavailable in the TBI field, the primary injury 
processes and related pathomechanisms are quite different; thus, the information is likely 
nonapplicable for TBI.  
CEREBRAL GLUCOSE METABOLISM  
Cerebral metabolism of glucose shows dynamic changes during development and after 
TBI. Adult cerebral metabolic rates of glucose (CMRglc) are achieved in the rat between 
35-45 days after birth (75 µmol/100g/min),16 and in humans by 16-18 years of age (26-27 
µmol/100g/min).17 These changes in the developmental profile directly influence changes 
in brain metabolism after TBI. Generally, after TBI there is a transient increase in CMRglc 
followed by a prolonged decrease in glucose uptake. It is important to note that CMRglc by 
positron emission tomography (PET) or 2-deoxyglucose autoradiography really 
demonstrate the uptake of glucose into brain cells up to hexokinase. It does not actually 
reflect glycolytic processing of glucose.  However, the dynamic changes in glucose uptake 














































































































































































































































































increase in glucose uptake that lasts 3-6 h in animals and 7-10 d in humans. Increases in 
glutamate and ionic disequilibrium are also detected during this phase. The lactate 
pyruvate ratio (LPR) reflects the balance between glycolytic contribution to the 
mitochondria and the anaerobic processing of pyruvate to lactate. The interstitial pyruvate 
and lactate are thought to be in equilibrium with the cytosolic compartment.18 Increases in 
LPR have been reported 1-10 d post TBI in numerous clinical studies and in experimental 
TBI. 19-20 Elevated LPR has been clinically documented after TBI in the absence of 
ischemia,19 shown to reflect the degree of cerebral damage,21 and is associated with poor 
outcome.22 The increase in LPR under these conditions may reflect changes in the 
glycolytic glucose processing. In energy state 2 (metabolic depression), there is a prolonged 
decrease in glucose metabolism, which is a  hallmark response to brain injury.23,24 During 
this second phase, there is a 9-12% increase in glucose shunting towards the pentose 
phosphate pathway.25 Glycolytic processing of glucose requires a constant supply of 
nicotinamide adenine dinucleotide (NAD+), which is decreased in the cytosol, thereby 
decreasing the carbon supply to the mitochondria.26-27 A consequence of these acute 
changes in glucose processing results in a decrease in ATP after TBI.28,29 Increased shunting 
of glucose towards the pentose phosphate pathway and/or impairments in glycolysis can 
decrease the production of pyruvate. Collectively these events disrupt the brain's energy 
production by decreasing carbon entry into mitochondria and creating a state of cerebral 
metabolic crisis that is thought to be reflected by the LPR. Ongoing cerebral metabolic 
dysfunction can lead to mitochondrial damage, energy failure, and neuronal loss after TBI. 
This dynamic TBI-induced metabolic pattern has been observed in various types of 
experimental TBI models, injury severities, age groups, and in human TBI. Timelines of 
CMRglc changes in animal TBI models and in human TBI will allow us to compare the 
species recovery profiles.  Relevant findings are illustrated on Fig. 1.     
Experimental studies 
Experimental models of TBI have been used with 14C or 18F labeled 2-deoxyglucose 
autoradiography/microPET to determine the magnitude and time course of metabolic 
changes after injury. Mild fluid percussion injuries have shown immediate increase in 














































































































































































































































































at 1 d and recovery by 7-10 d post injury in both the cortex and hippocampus.23 A similar 
pattern of CMRglc changes were also observed with 18F-deoxyglucose PET (FDG-PET) in 
adult mild fluid percussion injured rats with metabolic recovery by 16 d post injury.30 
Experimental data have shown that the magnitude and duration of CMRglc depression is 
dependent on injury severity. The temporal pattern appears to be similar in different 
models varying from fluid percussion to controlled cortical impact (CCI). While mild fluid 
percussion resulted in 20-30% decrease in CMRglc, more severe CCI injury models 
produced 50-70% CMRglc depression, which continued to remain depressed at 10 d post 
injury.31,16 Severe fluid percussion injuries have also been shown to induce chronic 
hypometabolism lasting 3-6 months after injury.32 Experimental studies have also shown 
that the magnitude and duration of CMRglc depression is affected by age. Postnatal day 
(PND) 17 and adolescent rats showed faster metabolic recoveries than adult rats following 
fluid percussion injury and CCI injuries especially in subcortical structures.33,16  
Clinical observations 
 Traumatic brain injury induced changes in CMRglc have also been analyzed in 
humans using 18FDG-PET. Mild TBI has been examined with FDG-PET by several groups, but 
many of these were at chronic time points, the result of motor vehicle accidents, and did 
not report actual CMRglc making it difficult to directly compare to experimental data.34-35 
These studies do report CMRglc depression in regions associated with specific cognitive 
functional tests. A comprehensive review of these studies has been compiled by Byrnes.30 
Moderate to severe TBIs have also been studied with PET, but as with mild injury studies, 
there is often a variety of ages, time points, averaging of cases, as well as an absence of 
time course profiles and reporting of metabolic rates.30 One study did show recovery of 
global cortical CMRglc depression following mild/moderate (GCS 9-15) in adult human TBI 
patients by 3 months but 6-9 months after severe injury.24, 36 Chronic CMRglc depression 
have also been reported after blast injuries, among comatose/vegetative severe TBI 















































































































































































































































































 In animal studies, the nadir is reached within 24 h after impact, whereas the 
greatest CMRglc depression is attained within the first week in humans. CMRglc recovery 
after mild fluid percussion injuries is 10-14 d in adults and 21-30 d after CCI injury. These 
data suggest that the TBI-induced CMRglc depression and the recovery are ~15 times 
faster in rodents than in humans. The differences between the rat and human timelines 
should be considered when trying to determine the estimated time for human CMRglc 
recovery as well as the therapeutic window for clinical trials.  
Significance of identifying the temporal pattern of CMRglc depression  
From a metabolic point of view, the time of altered (depressed) CMRglc 
corresponds to the period of increased cerebral vulnerability. During this window of 
heightened cerebral vulnerability, repeated injury leads to substantially more severe and 
longer lasting symptoms in both experimental and clinical TBI. Accordingly, identifying the 
exact temporal relationship between rat and human CMRglc changes is important for 
civilian as well as military TBI, especially for mild TBI / concussion.  
INFLAMMATION  
Inflammation involving microglia and astroglia as well as chemokines and cytokines 
is a key pathological response to TBI. Importantly, neuroinflammation appears to be the 
link between the acute response to injury and the development of chronic pathological 
processes that can lead to late-onset chronic neurodegenerative processes such as chronic 
traumatic encephalopathy (CTE). Similar to its role in other diseases, inflammation is a 
double-edged sword. In addition to its mostly recognized detrimental effects, 
inflammation plays a critical role in limiting the extent of cellular damage and facilitating 
recovery and repair. The ability to identify the point when the beneficial phase of the 
inflammatory response turns detrimental, is important for timing potential treatments. 
Equally important is the identification of the molecular and cellular components related to 
the various phases of the neuroinflammatory process. How closely the temporal profile of 
neuroinflammation observed in experimental TBI matches the process detected in TBI 
patients is currently poorly understood. Excellent reviews detailing the chemo- and 















































































































































































































































































however, they also illustrate the lack of temporal resolution in most of these studies. 
Outcomes between experimental and clinical TBI are likely only partly overlapping, thus 
knowing how the timescale found under experimental conditions correlate with the 
clinical process is important to establish the timing of the therapeutic intervention. 
Importantly, the neuroinflammatory process can be targeted with readily available anti-
inflammatory drugs, if we know the therapeutic window and the molecular targets. 
However, no pharmacotherapies that were proven successful in rodent models of sepsis or 
trauma have been similarly efficacious in clinical trials. One of the potential factors that 
may have contributed to these failures is that the therapeutic window was missed due to 
the different timelines between the rodent and human inflammatory processes. Relevant 
findings are illustrated on Fig. 2. 
Experimental studies 
How closely rodent models of inflammatory diseases mimic the human condition is 
the focus of intense and contentious debate. Comparing the genomic responses of human 
conditions with their relevant mouse models of trauma, burn, and endotoxemia has shown 
that at the whole genome level, there is very little similarity in human versus rodent 
transcriptional response and signaling pathways involved in the pathological response.41 
However, narrowing down the selection to genes involved in a subset of inflammatory 
responses showed more similarities in transcriptional response between rodent models 
and human cases. Importantly, the studies concurred that the temporal pattern of rodent 
versus human genomic response is very different. An important measure of the temporal 
pattern of the genomic response to inflammation is the time interval for the expression 
pattern to normalize. The time interval to return to normal (baseline) pattern of gene 
expression in the human burn cases averaged ~5 months (1 month to 1 year). In the 
rodent model, average recovery time was 3 days (1 day up to 7 days) suggesting a ~50-fold 
faster process in rats. Using a similar definition (return to normal pattern of gene 
expression) the recovery rate was found to be ~30-fold faster in the rodent model of 
trauma than in humans. Interestingly, the recovery rate was similar for endotoxemia, 
around 1 day in both humans and rodents. However, the genomic responses themselves to 














































































































































































































































































Longitudinal studies tracing microglial response to injury by PET imaging enables 
comparison of the neuroinflammatory timelines between human cases and rodent models 
of TBI. The most comprehensive experimental longitudinal study by Wang et al. (2014) 
used a combination of PET imaging with [18F]-714,42 a specific ligand to the 18 kD 
translocator protein (TSPO) for activated microglia, ex vivo autoradiography, and 
immunohistochemical verification of the PET and autoradiography data. An important 
caveat is that the various PET ligands also bind to TSPO in (activated) astrocytes, and thus 
TSPO should be considered a marker of activated astro- and microglia. 43, 44 The study 
showed that the neuroinflammatory response, as detected by  all three methods, peaked 
at around day 6 after controlled cortical impact (CCI) injury. TSPO expression declined by 
day 10 and returned to the levels measured in the sham treated group by day 28. This 
timeline was confirmed by in vitro autoradiography and also by immunohistochemical 
staining of activated microglia. These findings are in agreement with previous PET studies 
using different ligands ([11C]PK11195 and [18F]FE-DAA1106) for activated microglia. 45 
These studies also showed maximum neuroinflammatory (microglia) response around day 
6-10 post-injury that returned to normal levels by around 30 days post impact. It should be 
noted that activated astroglia as well as peripheral macrophages also bind TSPO, thus the 
protein is not entirely microglia specific. However, other cell types are also involved in 
mediating the inflammatory response after TBI.  
Clinical observations 
There are significant challenges in comparing the temporal sequence of 
inflammatory events in rodent models vs. human TBI. A key consideration in human 
neuroinflammation research is defining ‘inflammation’ in the first instance. If 
‘inflammation’ is considered as the endogenous response to injury, it has to cover a wide 
spectrum of both humoral and cellular events that span both innate and adaptive 
immunity.46 Access to a number of biological compartments (plasma, CSF, brain 
extracellular fluid) has allowed researchers to measure a range of inflammatory 
biomarkers following TBI but each of these biocompartments has its limitations with 
respect to interpretation. For example, plasma sampling is confounded by extracranial 














































































































































































































































































for clearance of inflammatory substances;47,48 and microdialysate sampling from the brain 
extracellular space is limited by the proportion of a soluble mediator that crosses into the 
microdialysis catheter which varies with molecular weight, charge and methodological 
variations in microdialysis technique.49 The absolute concentrations of a given mediator 
are therefore difficult to relate directly to equivalent rodent studies when extrapolating 
data on the range of concentrations that may inflict neuronal injury. Human TBI research is 
necessarily opportunistic and very early events that occur in the clinical resuscitative phase 
are beyond the reach of clinical studies that require sampling of biological fluids. However, 
an early post-mortem study carried out on patients succumbing to traumatic brain injuries 
at various intervals has empirically demonstrated that at the mRNA and protein level, early 
pro-inflammatory drivers of innate inflammation, including IL1β and TNF, are significantly 
increased in the human brain within 24 h after TBI.50 Following this early period, once 
patients are admitted to specialist neurointensive care, invasive monitoring allows a more 
detailed assessment of inflammatory biomarkers. Interestingly, serendipitous monitoring 
within the first 24 h picks up this early pro-inflammatory signal while subsequent 
monitoring time points do not.47 Beyond this time frame, a strong IL6 signal has been 
detected within the first 24-72 h in both microdialysate and CSF.47,51,52,53 IL6 is an 
interesting cytokine as it may have both damaging and protective properties depending on 
the context in which it is produced.54 In absolute terms, IL6 is produced at concentrations 
several orders of magnitude higher than IL1β and TNF,47 which may introduce a selection 
bias into the literature as it is easier to detect analytically. 
Alongside these key cytokines, several chemokines are detected and likely reflect 
recruitment or activation of inflammatory cells. GRO-alpha and IL8 are produced in the 
first 24-48 h and may reflect neutrophil recruitment. Beyond this, chemokines related to 
microglial activation, recruitment, activation, and expansion are found in an overlapping 
time frame including monocyte chemoattractant protein 1 (MCP1/CCL2), regulated upon 
activation normal T cell expressed and secreted (RANTES/CCL5), and granulocyte colony 
stimulating factor (GCSF). When comparing studies, it is important to interpret the data in 














































































































































































































































































late IL10 response at around day 4-7 may subsequently reflect a shift in microglial 
activation towards a reparatory or regulatory phenotype.47,55  
 Several authors have considered the role of these inflammatory biomarkers in TBI 
pathophysiology and correlated concentrations with specific sequelae rather than 
considering the temporal sequence per se.56,57 Several studies relate this acute response to 
chronic sequelae,58, 59 and outcomes at 6 months following TBI,60, 61 suggesting that this 
acute response plays a mechanistic role in inflicting injury.  
In the chronic phase, there is evidence that the plasma cytokines (IL1β, IL6, IL8, and 
IL10) are raised for over 3 months following injury and this may relate to clinical outcomes, 
albeit demonstrated in small groups of patients.61 While no comprehensive study similar to 
Wang et al. (2014) is available for human TBI patients, 42 published works indicate that the 
inflammatory response, as defined by the presence of activated microglia, persists for 
many years after the injury. Using the ligand [11C]PK11195, Ramlackhansingh et al (2011) 
have found activated microglia persisting in patients up to 17 years after TBI.62 
Interestingly, the patients showed persistent activation of microglia distant from the lesion 
site, raising the possibility that this represents diaschisis or a long-lasting reorganization 
that underlies plasticity and recovery, distinct from the original injury. These findings are 
consistent with data obtained from post-mortem studies showing long-term presence of 
activated microglia ~16 years after TBI as well as studies performed in non-human 
primates showing substantial neuroinflammation one year after injury (the latest time 
point studied) indicating that TBI induced neuroinflammatory response can be 4 to 30 
times faster in rats than in humans (Summarized in Fig 2). An additional and often 
underappreciated aspect of inflammation is the adaptive immune response.63 There is a 
paucity of clinical studies in this context but information about the additional phase of 
autoimmunization over a 10 to 14-day typical study period is missing. 
Significance of identifying the temporal pattern of inflammation  
The importance of defining and targeting an appropriate therapeutic window has 
been well-described in the TBI literature. Inflammatory processes are a promising target in 














































































































































































































































































clinical intervention. Nevertheless, there are several caveats that must be considered. A 
relatively small group of cytokines and chemokines has been measured in the clinical TBI 
literature,46 and as these mediators act in complex cascades and show a high degree of 
collinearity it is impossible to draw conclusions about causality from observational 
correlative studies. When choosing putative therapeutic targets, an assessment of the 
biological consequences of administration should provide confirmation that the drug is 
exerting the desired effect.64 Furthermore, with the heavy bias in the literature towards 
assessment of soluble mediators, there is ambiguity over the cellular origin of the 
measured cytokines and chemokines. Microglia, astrocytes, neutrophils, and neurons are 
all capable of producing these mediators.46 Considering the functional heterogeneity of 
these cells, immunomodulatory pharmacotherapies may require delivery at specific times 
to target distinct cellular subsets to have a beneficial effect. 
From a therapeutic point of view, the onset and extent of the inflammatory 
response to injury represents a window for anti-inflammatory therapies. Given the 
abundance and availability of anti-inflammatory therapies that target specific molecules of 
the inflammatory process, it is critical that the temporal differences between rodent and 
human inflammatory response are taken into account when trying to identify the 
therapeutic window for anti-inflammatory molecules in clinical trials.  
VASCULAR PERMEABILITY CHANGES AND EDEMA  
A frequent consequence of TBI is altered water homeostasis manifested as cerebral 
edema, particularly in severe TBIs. Cerebral edema is broadly classified as either vasogenic 
or cytotoxic (cellular) edema. The former occurs due to increased vascular permeability to 
proteins, resulting in increased water content of the extracellular space, while the latter 
occurs due to water accumulating in the intracellular space because of abnormal ionic 
distribution caused by increased ion channel permeability and/or inefficiency of ion 
pumps. Although the two forms of edema are considered distinct, in reality one form 
usually leads to the other and the two mechanisms often overlap. Indeed, vasogenic 
edema following TBI has been found to be permissive for cellular edema.65 Generally, 














































































































































































































































































edema dominates in the grey matter.66 The development of edema is initiated by vascular 
and/or metabolic events, with inflammation contributing to both onset and persistence of 
cerebral edema. Relevant findings are illustrated on Fig. 3. 
Experimental Studies 
Following experimental TBI, there is a rapid edema formation within the first hour 
which diffusion-weighted magnetic resonance (MR) imaging studies have shown as 
vasogenic edema.67,68, 69 The presence of a blood brain barrier (BBB) that is more 
permeable to vascular proteins has confirmed the vasogenic nature of the edema.70 The 
initial increased permeability of the BBB to large vascular proteins was, however, limited 
to the first few hours after TBI with the BBB becoming increasingly less permeable to 
vascular proteins and normalizing over the next week.70,71 As the BBB became less 
permeable, cytotoxic edema became more apparent, signifying a net movement of water 
from the extracellular to the intracellular compartment. Maximum cytotoxic edema was 
observed between days 7 and 14 after TBI, resolving thereafter.68, 69 
Some reports have suggested a second increase in BBB permeability to vascular 
proteins on day 3,72 which may lead to a surge in intracranial pressure (ICP). While not 
universally observed in all models of experimental trauma, this second opening of the BBB 
is consistent with the reported delayed tight junction breakdown,73 most likely mediated 
by activation of matrix metalloproteinases. This is in contrast to the functional transcytotic 
upregulation of albumin transport, with tight junctions intact, seen in the early phase after 
TBI,73,74 and indeed as early as 3 minutes after TBI.75 Such delayed opening of the BBB 
suggests the involvement of brain metabolic processes and inflammation that are initiated 
by the injury in contrast to a largely neural/vascular interaction in the immediate post-
injury period.76 
Clinical observations 
Studies of edema and BBB permeability in patients have been difficult given the 
inherent instability of TBI patients, particularly those that are severely injured, and when 
imaging studies are potentially complicated by mechanical ventilation. Nonetheless, there 














































































































































































































































































Both vasogenic and cytotoxic edema have been reported after TBI using magnetic 
resonance imaging (MRI) techniques,77 although a predominance of cytotoxic edema is 
noted as time progresses with any subsequent tissue loss being replaced by extracellular 
water.78 MRI-detectable abnormalities in BBB permeability were more common in 
pericontusional areas after 2 days, and frequently did not become apparent until 6 days 
after injury.79 This is consistent with the strong association between hemorrhage and 
activation of metalloproteinases, and the observation that persistent increases in 
metalloproteinases have been reported after 4 days in clinical TBI.80 
An alternative to imaging studies is the use of CSF- and serum inflammatory 
biomarkers or albumin distribution to indirectly determine increased BBB permeability.81, 
82 These studies have confirmed the MRI findings indicating BBB dysfunction in the days 
following TBI. Irrespective of the technique used, it has been noted that patients with 
increased BBB permeability have poorer outcomes,83 with those with more severe 
disruptions of BBB after 3 days being predisposed to developing substantially higher ICP 
values.81 The development of increased ICP in the presence of a permeable BBB implies a 
continuing role for vasogenic edema after clinical TBI.83 BBB permeability is generally 
thought to return to normal within several weeks, although persistent BBB dysfunction has 
been reported months to years later in patients who develop post-traumatic epilepsy and 
even after mild TBI. 84 
Consistent with experimental studies, increased transcytosis of vascular protein 
while endothelial tight junctions are intact has been reported in the first hours following 
human TBI.85 However, this transcytosis persists for up to 2 years post-injury.86 More 
severe edema at these later time points was also associated with opening of the tight 
junctions, perhaps reflecting the involvement of metabolic processes and inflammation 
initiated by the injury (once again) at these delayed time points. 
Significance of identifying the temporal pattern of vascular permeability and edema 
 While the immediate functional vascular response of rodents to TBI is very similar 
to that of humans, subsequent metabolic and inflammatory responses that underlie BBB 














































































































































































































































































Indeed, the majority of studies in experimental animals describe BBB restoration within a 
month after CNS lesions. Conversely, increased BBB permeability and edema formation 
has been noted years after the traumatic event in humans. 87-89 Not only would this result 
in an extended period of injury development with a consequent lack of functional recovery 
in humans, but it also implies that the therapeutic opportunity for intervention at the 
metabolic and inflammatory level extends well beyond the weeks assumed from rodent 
studies. Important caveats include the type and severity of the injury. Severe TBI is rarely 
modeled in rodents and few studies focus on penetrating / ballistic injuries. Moreover, the 
methods used to monitor BBB function in rodents and humans are in most cases vastly 
dissimilar, contributing in part to the limited understanding of the temporal differences in 
vascular permeability that exist between the two. Additional difficulties include the 
unknown onset and extent of neovascularization after TBI observed in both rodent models 
and also in human TBI cases.90 Newly formed, immature vessels have increased 
permeability and we currently do not know how long it takes until de novo vessels develop 
fully functional BBB in the rodent models versus in human TBI cases.  Recent study has 
shown that in a rodent model of mild TBI, the inflammatory process can trigger 
revascularization as part of the endogenous repair program repair but only within a 
specific, delayed window period during which would-healing macrophages promote 
angiogenesis. 91 This finding further underlines the critical importance of understanding 
the differences between rodent and human pathological processes.  
 AXONAL INJURY  
Axons in the CNS are especially vulnerable to the impact of physical forces; therefore, 
traumatic axonal injury (TAI) is a major pathological change after TBI.86 Severe kinetic 
impact can shear or break axons resulting in primary axotomy. Less severe impact results 
in membrane disturbances, dislocated ion channels, and dislodging of the axoskeletal 
network with subsequent disruption of axonal transport. These initial (primary) changes, 
especially when combined with prolonged ionic and metabolic perturbations during the 
secondary injury process, may lead to axonal swelling, retraction bulbs, and to neuronal 
cell death. Diffuse axonal injury (DAI) that predominantly affects white matter (WM) 














































































































































































































































































large animals with gyrencephalic brains. TBI-induced axonal pathology is more localized in 
the rodent brain and the term “traumatic axonal injury” (TAI) is frequently used. The 
pathomechanism of DAI and TAI is likely very similar if not identical so the difference 
between DAI and TAI is probably only in the semantics. DAI majorly contributes to the 
clinical manifestations of TBI, loss of consciousness and coma in the acute phase of severe 
TBI, and cognitive and functional impairments in survivors of severe TBI. While the initial 
physical impact and the associated metabolic changes result in acute disruption of axonal 
structure and functions, there are also delayed axonal pathologies. They evolve over time 
and may last weeks and months after the initial impact as other pathologies of the 
secondary injury processes, metabolic changes or inflammation can affect the evolution 
and resolution of axonal injuries. 
When matching the temporal course of central axonal injury in rats and humans it 
must be understood that DAI is a large animal disease expression and the term generally 
used for gyrencephalic animals. The rodent has relatively less white matter and animal 
models producing TAI may not be immediately comparable to the distribution of local 
lesions in larger species. Additionally, the rotational forces required to produce human DAI 
like changes, may be hard to reproduce in small volume skulls and in animals with few or 
no gyri. Impact models of rats where brain parenchyma will have little rotational mass and 
possibly different and more transient loss of consciousness responses to DAI injury than 
humans, has led to debate on how comparable rodent models are to the human condition. 
95 
Traditionally, axonal injuries are mostly identified by using various 
histopathological methods, using beta amyloid B precursor protein (APP) 
immunohistochemistry or silver impregnation. APP accumulates due to the disruption of 
axonal transport system and APP-immunoreactive structures are indicative of axonal 
injury.96-98 Variations of silver impregnation methods visualize degenerating (or perturbed) 
membranes including axons and claimed to be more sensitive assay for TAI (or DAI) than 
APP immunohistochemistry.99, 100 It should be noted that the two methodologies detect 
distinct perturbances in axonal morphology and function. In clinical settings, DAI is 














































































































































































































































































studies making the comparisons between human and rodent timelines challenging. 
Various modalities of DTI indicate white matter changes and the oft accompanying micro-
hemorrhage can be seen with Susceptibility Weighted Imaging (SWI).101-103  
Structural elements of the axoskeleton, the low, medium and high molecular 
weight neurofilament proteins (NF-L, NF-M, and NF-H, respectively) and tau are highly 
enriched in the nervous tissue. Injury increased levels of these proteins in the blood (and 
CSF) have shown correlation with the onset and extent of axonal injury both 
experimentally and clinically enabling improved comparisons between clinical and 
experimental data.104-108 Injury-induced disintegration of the axoskeleton is mediated by 
calcium-dependent enzymes calpain and caspase-3. These enzymes are activated by the 
sudden rise in intracellular calcium levels and the activated enzymes then breaking down 
spectrin. Axonal damage mediated by calpain and caspases is reflected in patterned 
breakdown of all spectrin breakdown characterized by known protease cleavage points, 
and calpain and caspase activity can be attributed based on predictable lengths of αII 
spectrin breakdown product (SBDP) produced after cleavage.109, 110 αII spectrin is a 
component of the cytoskeleton and connects axolemmal components to the presynaptic 
terminal, stabilizing the nodal structure of myelinated axons. Calpain lyses the spectrin 
cytoskeleton into SBDP 145 and SBDP 150, and caspase-3 renders SBDP120.111 
Consequently, the relative contribution of each of these calcium-dependent proteases 
makes cytoskeletal breakdown potentially distinguishable. With significant increases in 
intracellular calcium immediately following injury, calpain activity rises between 8 and 12 h 
after injury peaking at 24 h before decreasing to lower levels by 3 days. The time course of 
primary axonal damage caused by the physical impact can be further extended by hypoxia 
112 that -among its other effects- increases intracellular calcium levels. Relevant findings 
are illustrated on Fig. 4. 
Experimental studies 
Studies using rotational or acceleration/deceleration forces to cause axonal injury 
have shown that TAI occurs within minutes in the rat as shown by using dextrane as 














































































































































































































































































as early as 15-30 min after TBI using APP immune-fluorescence.113, 114 Intra-axonal changes 
begin immediately after the impact and axonal swelling and detachment develops within 
the first day (12-24 h) after injury. APP accumulation in the rodent TBI model can be 
detected up to 14 days after injury.115 Hellewell et al.  demonstrated a maximum number 
of retraction bulbs at day one with a gradual decrease at 14 days post injury.112 A key study 
by Mac Donald et al (2007) established the temporal pattern of TAI in a mouse model of 
CCI using a combination of histology, electronmicroscopy, and DTI.116 The study showed 
that the numbers of both APP and NF-L positive axonal varicosities increased dramatically 
during the acute phase of injury defined as between 4-6 h and 4 days post impact followed 
by a substantial decline during the subacute phase -1 week to 1 month. Importantly, 
quantitative analysis of DTI parameters - axial diffusivity (AD), radial diffusivity (RD) 
relative anisotropy (RA) and mean diffusivity (ADC) - showed close correlation with the 
histological findings. AD decreased during the acute phase and returned to control levels 
by 1 month while RA levels remained reduced during both the acute and subacute phase.  
Li et al. saw an increase in APP stained axonal varicosities up to 72 h. They also 
found that the temporal profile of the immunohistochemical staining correlated very 
closely with that of changes detected by DTI. Both fractional anisotropy (FA) and AD were 
significantly reduced in the brain regions affected by the trauma between 3 to 72 h.117 
These findings are important because they suggest that changes detected by DTI, reduced 
FA and AD can reflect the histological underpinning of TAI.116, 118 There appears to be 
evidence of late demyelination in the rat at 4 weeks,116 as compared to humans where 
demyelination is still detectable at 1-4 years after the injury. As discussed above, activated 
glia cells and macrophages, indicating inflammatory processes, have been shown to peak 
around day 3-7 post-injury in the rodent model. 
Clinical observations 
DAI is a common pathological feature of closed head TBI, especially severe TBI.92, 93, 119 
Clinically, DAI is characterized by early loss of consciousness and often exhibits 
disproportionately limited focal lesions in the brain on computed tomography scans. 














































































































































































































































































The brain regions that most commonly show DAI injury are the subcortical grey-white 
matter interface near the frontal and temporal lobes, corpus callosum, and brainstem.122 
DAI results in impaired cognitive, autonomic, and sensory functions depending on the 
extent of lesions and affected brain regions, with clinical severity generally increasing the 
deeper the structure(s) involved. The severity of DAI can be classified  from Grade I (mild) 
characterized by subcortical and internal/external capsule lesions; Grade II (moderate) in 
addition to the above regions the damage affects the corpus callosum (CC); Grade III 
(severe) with additional lesions in the brainstem.120 As with other pathobiologies triggered 
by TBI, the primary DAI is instantaneous while the secondary DAI can last for an extended 
period of time.  
It was long believed that DAI was part of the acute to subacute pathological 
response to TBI; however, there is strong indication that DAI can persist years after the 
insult. The original focus on immediate shearing forces and retraction bulbs of severed 
axons followed by Wallerian degeneration has been expanded by a growing appreciation 
of the extended metabolic disturbance initiated.123, 124. This is thought to involve calcium 
dysregulation, disruption of ionic homeostasis, energetics and cytoskeleton breakdown 
leading to axonal swelling and glial activation, followed by an extended period of 
inflammation, possibly lasting for years.124 Histological evidence of DAI has been seen in 
human forensic material as early as 35 minutes after injury,119 and axonal swelling and 
beading size has been seen to progress up to 24-48 h,125 where milder trauma exhibits a 
slower swelling. Additionally, this has been seen to be a non-homogeneous process with 
much local variation. The temporal progression of DAI on MRI has been investigated but 
the great variability in timing within and between MRI studies makes a clear sequential 
picture hard to delineate. TBI is however associated with general WM loss over time, in 
excess of the natural loss seen in age matched controls. The time course of human DAI as 
seen on MRI has been suggested to be divided into four stages: acute (< 24 h), early sub-
acute (1-13 days), late sub-acute (14-21), and chronic (> 21 days) where early lesions are 
generally superseded by local edema in the sub-acute phases and by general white matter 
loss in the late chronic stage.126-129 DTI detection of DAI focuses on non-uniform or 














































































































































































































































































diffusivity. Early changes over the first week may thus be confounded by edema, exhibiting 
either restricted (intracellular, days) or increased (extracellular, 1 to 2 weeks) water 
movement. Late chronic stages may show a continuation of WM loss for years. Grey 
matter loss may be a faster process and has been seen to diminish at 3 months,130 whereas 
late volume loss appears to be WM-related.131 Bendlin et. al. identified continued WM loss 
at one year post trauma.132 In a follow-up study of this cohort of mild-severe TBI patients, 
WM changes in the corpus callosum using DTI were seen to progress most the first year 
after trauma but continue up to four years.131 Importantly, reactive microglia were also 
detected in white matter tracts that showed axonal pathology, suggesting that persistent 
axonal / white matter pathology may be the result of a chronic neuroinflammatory 
process.133 Interestingly, in this late follow-up, radial diffusivity (water movement 
perpendicular to axonal tracts) was more affected than axial diffusivity (along tracts), 
leading the authors to conclude that late pathology was driven more by myelin changes 
than axonal changes. However, a recent study that followed moderate to severe TBI 
patients longitudinally for at least at 3 time points,134 from the acute through chronic 
phase (medians: 1 week, 7 and 21 months), found late alterations to be driven by changes 
in both radial and axonal diffusivity. Additionally, the inflammation process may persist for 
years.62, 135 Although candidate protein biomarkers exist, none have yet been established 
to follow the evolution of DAI. Neurofilament light (NF-L) is seen to increase for days to 
weeks after injury and levels have been related to outcome. However, NF-L levels have not 
been clearly related to MRI findings. In aggregate, the time course of DAI in humans is a 
process with early and late pathophysiological components where changes can be ongoing 
for years.  
Significance of identifying the temporal pattern of axonal injury 
The temporal pattern of axonal injury appears to be comparable between rodents and 
humans during the acute phase of the injury. It is the sub-chronic and chronic phase of TBI 
where the temporal patterns differ. In the absence of a new physical impact, the late 
phase of axonal injury is likely caused and maintained by other TBI-induced metabolic and 
inflammatory abnormalities.93, 97, 133 Mitochondrial abnormalities, oxidative stress, and 














































































































































































































































































elevated intra-axonal Ca++ level. Neuroinflammation that can persist for years in humans 
after TBI can cause similarly lasting, chronic axonal degeneration.136   
Given the limited ability of the mammalian CNS to regrow lost or dysfunctional 
axons, the most beneficial therapeutic interventions are likely aimed at 
restoring/normalizing cerebral metabolism, buffering neurotoxicity, and modifying the 
neuroinflammatory process.93 There are important caveats that include the relative low-
fidelity modeling of axonal injury in rodents due to anatomical differences discussed above 
and the unknown contributions of the distinct secondary injury processes to the overall 
response to injury. These, in combination with the type of injury (i.e., closed head or 
penetrating, focal or diffuse) can majorly determine the relative contribution of axonal 
injury to the overall secondary injury process. DAI in clinical practice is a complex injury 
that is frequently associated with bleeding or microbleeding and often accompanied by 
other lesions. Bleeding, an indicator of vascular injury detectable by imaging, is an 
important (if not critical) comorbidity that further complicates the secondary injury 
process. Additionally, aging can affect the outcome of axonal injury. There are indications 
that the vulnerability of axons to physical impact is affected by age and age can affect 
recovery. 137-139  
The duration of ongoing axonal pathology reflects the period of increased cerebral 
vulnerability, i.e., when re-injury can trigger disproportionally severe consequences by 
rendering changes to axons irreversible and resulting in axonal losses. Rehabilitation 
therapies, when optimally timed, can result in substantial functional recovery. Better 
knowledge of the duration and trajectory of axonal pathologies in rodents versus humans 
will help to identify the window for such interventions. In summary, the experimental 
relationship between human and rodent DAI/TAI may not be immediately comparable, but 
evidence suggests that the temporal changes in the acute phase may be similar between 
rodents and human cases. However, the late and chronic phases of DAI suggest that the 
















































































































































































































































































DISCUSSION and RECOMMENDATIONS 
TBI is a dynamic condition even in its mildest form; clinical symptoms and underlying 
pathobiological responses substantially change over time. Neuromonitoring data best 
illustrate the dynamics of time-dependent changes in the onset and extent of select 
pathobiological responses after severe injury.140-142 Despite the importance of identifying 
“therapeutic windows” for various interventions, only a fraction of studies addresses the 
temporal aspect of the TBI molecular sequelae. Of the approximately 38,000 publications 
found in PubMed, using “traumatic” AND “brain” AND “injury” as search terms, only 1,626 
(4.3%) covered (some) aspect of time-dependent changes of the disease. Of the 
approximately 12,000 clinical studies, using the search terms “traumatic” AND “brain” AND 
“injury” AND “clinical,” only 486 (~4%) addressed (some) aspect of time-dependent 
changes (using these additional search terms of “time” OR “temporal”) of the TBI disease 
process. The proportion is similar in preclinical/experimental TBI, only ~450 of the total 
publications (~2%) addressed (some) temporal aspects of TBI. Because of the simplicity of 
the PubMed search, these percentages are not exact but clearly illustrate the relative lack 
of data that would help to determine the temporal profiles of pathobiological changes, 
and consequently help to identify the therapeutic windows for various pharmacological 
treatments.  
Recommendation #1: We recommend conducting more longitudinal studies, collecting and 
reporting data at multiple post-injury time points. This will increase the data density 
necessary to characterize the profile and evolution of injury-induced changes. Specifically, 
data should be collected at 2-3 three times the rate of the expected information content of 
the temporal signal studied, as expected by the experimental hypotheses (Nyquist 
frequency).143 In the absence of such a hypothesis, and without the possibility of high 
frequency sampling, an initial sample frequency along a geometric time series multiple of 2 
(0.5, 1, 2, 4, 8, 16 time-units) can help to identify the required sampling frequencies/ time-
points for a specific early biomarker.  
Developing an algorithm for “translating time” between rodent and human TBI 














































































































































































































































































injury severity and different outcome measures in rodent TBI studies vs. clinical cases. 
Classification has played an essential role in our understanding and treatment of diseases. 
Subdividing complex diseases into smaller, more homogeneous sets of pathologies has 
increasingly enabled accurate diagnosis, prognosis, and the development of specific 
treatments. However, TBI greatly lags behind other much better characterized diseases, 
such as cancer, when it comes to classification. Cancer is now subdivided into smaller 
subclasses, each with more homogenous molecular pathologies, increasingly enabling 
personalized, evidence-based treatments. TBI is an acquired, sudden-onset disease with 
dynamically changing pathobiological processes. Therefore, knowing the identity, onset, 
and extent of the various pathobiological processes is fundamental for developing a 
molecular-level classification system and evidence-based treatments for TBI. Current 
classification is still based on rather subjective clinical observations, and neuroimaging 
findings to a lesser extent, but not on molecular criteria. Experimental TBI studies 
generally lack even this subjective classification system. In clinical TBI, the Glasgow Coma 
Scale (GCS), length of loss of consciousness (LOC), alteration in mental/conscious sate 
(AOC), and post-traumatic amnesia (PTA) are used for classification. Due to their ease of 
use, practically every clinical TBI report contains GCS (and some LOC, AOC, and PTA) scores 
that are used for triaging, assessing disease progression, and selecting patients for clinical 
trials and epidemiology studies.144-145 Similarly simple and subjective tests, such as the 
Glasgow Outcome Scale (GOS), are used to assess outcome and the efficacy of the 
pharmacological or other intervention in most clinical trials. In contrast, most experimental 
TBI studies do not report injury severity; available neurobehavioral classifications, for 
example the Neurology Severity Scale (NSS),146 or the duration of post-injury apnea, 
regaining of the self-righting reflex, and so forth are rarely used and/or reported. Although 
the use of anesthesia is a major confounding factor in experimental TBI, classifying injury 
severity using standardized neurobehavioral assessments could provide critical 
information to better compare between experimental and clinical TBI cases.  
Recommendation #2: We recommend that relevant organizations, such as funding 
agencies and scientific journals, encourage or even require the reporting of NSS or similar 














































































































































































































































































combined with increased identification and utilization of clinically-relevant, molecular-
level proxy outcome measures (e.g., biochemical or imaging markers (see 
Recommendation #3 below), will increase our ability to directly compare injury severity 
between clinical and experimental cases and will increase our ability to more directly 
compare the temporal patterns of various molecular pathologies as a function of injury 
severity. 
TBI triggers an array of pathobiological responses, depending on the type and severity 
of impact. To better understand the temporal differences between rodent and human TBI-
induced pathological processes, the identity, onset, intensity, and extent of the various injury-
induced pathological changes should be determined using objective, quantifiable outcome 
measures that are identical (or at least comparable) to clinical TBI studies. In clinical TBI 
research, the severe form of TBI is the most studied, and the disease process is best 
documented. Severely injured patients are admitted to neurointensive care and are evaluated 
and constantly monitored by neurocritical care specialists.147-149  Neurocritical Care monitoring 
provides real-time data on physiological parameters, such as blood pressure, breath, heart and 
pulse rates, blood oxygen saturation, and intracranial pressure, in addition to local and global 
methods of assessing cerebral blood flow (CBF), oxygenation, and metabolism. No equivalent 
preclinical data exists, although there are simple tools available for the physiological 
monitoring of rodents.150, 151 For ethical reasons, modeling severe TBI in animal models is 
virtually non-existent; therefore, we cannot really compare the most data-rich clinical studies 
(severe TBI), where the main outcome measure is survival, to experimental TBI data. 
Conversely, experimental studies mostly model mild to moderate forms of TBI, making these 
types of preclinical studies the most data rich. Clinical studies are conducted on 
heterogeneous populations where confounders, such as age, gender, comorbidities, 
medications, and pre-hospital/hospital care, are not replicated in the animal-based 
experimental setting. This heterogeneity is hard to overcome and resolve in an experimental 
setting, but at least the effects of age and sex may be investigated.  Moreover, the most 
clinically studied, albeit least frequent forms of TBI (i.e., moderate to severe) are typically part 
of polytraumas that cause other organ injuries, bone fractures, and so forth. In experimental 














































































































































































































































































Recommendation #3: Funding agencies, scientific journals, and other regulatory bodies 
should encourage or even require the use of clinically-relevant outcome measures in 
experimental TBI such as neurobehavioral monitoring, structural imaging, and biochemical 
markers in the peripheral blood and/or cerebrospinal fluid (CSF) at multiple post-injury 
time points. In combination with outcome measures that are unique to experimental TBI 
research, e.g. histopathology these clinically relevant data will help to better identify the 
pathological processes and their temporal patterns. 
Experimental and clinical TBI studies generally use different tools and 
methodologies to identify underlying pathologies. In the absence of identical or at least 
comparable outcome measures, the temporal patterns of pathobiological processes in 
rodents versus humans cannot be precisely determined. In vivo imaging, mostly computed 
tomography (CT) but also MRI/DTI, are key determinants of structural damage in the 
clinical setting. Serial neuroimaging is often used to assess disease progression. However, 
imaging is currently infrequently used in pre-clinical TBI studies to generate enough data 
for comparison, and serial imaging studies are extremely rare in experimental TBI research. 
Structural information in experimental TBI has been overwhelmingly obtained via terminal 
histopathology, which is not very useful for determining the evolution of pathological 
changes in clinical TBI. The proxy outcome measures that are most commonly used in both 
experimental and clinical TBI are blood-based protein biomarkers. However, serial 
sampling in experimental TBI is rarely performed and in the absence of comparable injury 
severity classifications in experimental and clinical TBI, and lack of established relations to 
functional outcome, the comparison of available protein biomarker data is challenging.    
Translating time? Based on the available data, some of it discussed in this review, it 
appears that there is no universal “X factor” that can be used to “translate time” between 
rodent and human pathobiological changes. Normal biological and pathobiological 
processes seem to run faster in the rodent than in the human.14 Normal metabolic, 
physiologic and developmental processes, such as RNA turnover, respiratory rate, 
gestation, and senescence, are about 2.5 to 84 times faster in rodents than in humans. 
Thus, 1 human day can roughly equal 2 rat hours during gestation or 0.3 rat hours during 














































































































































































































































































when attempting to model neurodegenerative diseases like Alzheimer’s or CTE in rodents 
when the life expectancies of the two species are so vastly different? As illustrated above, 
the rate for rodents can be 15 or 100 times higher, respectively, in TBI-induced changes in 
CMRglc and neuroinflammation. In other words, there is no universal conversion rate.  
The most probable way to successfully “translate time” is to use a big data (BD) 
approach.152, 153 However, successful BD approaches are critically dependent on the 
volume of data. In theory, BD could generate new knowledge by mining the available 
~40,000 legacy TBI publications. Neuro-linguistic programming (NLP) is rapidly improving 
and can be used to identify repeatable patterns such as relationships and correlations 
between the temporal patterns of rodent and human pathobiological processes. However, 
it appears that published TBI data is not (yet) sufficiently big for BD.154 It has been 
calculated that only a fraction of the data generated during experimental or clinical TBI 
studies is ever published, deposited, or made available in databases or other archives.155 
Conservative estimates put the amount of unpublished, so-called “dark data,” to more 
than 50% of all data generated. Accordingly, publications only represent a fraction of all 
data and importantly, the published data is typically “curated” (i.e. “selected” from a much 
larger pool of data) making the BD approach prone to subjectivity and bias. Efforts by the 
NIH and other agencies, requiring the use of common data elements and the deposition of 
all experimental data, will increase the availability of experimental data for mining and the 
accuracy of potential algorithms that could be used to “translate time.” Such a BD 
approach could and will go beyond translating time, as it will enable more precise 
predictions of relationships between various pathological processes, species, and diseases, 
thus guiding hypothesis generation and clinical trials based on compounded and weighted 
evidence.  
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FIG. 1. Time-related changes in cerebral glucose metabolism after different types of 
traumatic brain injury (TBI) in rats (dashed lines) and humans (solid lines). Data are 
expressed as a percentage of baseline (either sham or control) values. (A) Data from adult 
rats with unilateral fluid percussion injury using in vitro autoradiography of [t4C]2-deoxy-
D-glucose to determine changes in the rate of cerebral glucose utilization.26 (B) Summary 
of in vitro autoradiography of [t4C]2-deoxy-D-glucose data following cortical contusion in 
adult rats showing changes in the rate of cerebral glucose utilization.16,36 Data summarizing 
the effect of (C) moderate and (D) severe TBI in humans using FDG-P to determine changes 
















































































































































































































































































FIG. 2. A comparison of the temporal changes in inflammatory response after different 
types of insults in rodents (dashed lines) and humans (solid lines). Transcriptional response 
after (general) trauma in (A) rodents and in (B) humans. Data are expressed on a log2 
expression vs. time scale to illustrate instances where genes significantly changed over 
time in human injuries, albeit minimally in murine models.45 (C) Microglial activation after 
controlled cortical impact in rats as detected by positron emission tomography (PET) 
imaging, ex vivo autoradiography, and verified by immunohistochemistry.46 (D) Microglial 

















































































































































































































































































FIG. 3. Comparisons of the time course of changes in cerebral edema detected by 
neuroimaging and/or by biochemical methods after different types of insults in rodents 
and humans. (A) Diffusion-weighted magnetic resonance (MR) imaging showed increased 
hyperintensity after moderate fluid percussion TBI,68 likely the result of vasogenic cerebral 
edema. (B) Cytogenic edema peaked around day 7 following impact acceleration (diffuse, 
closed-head) injury, and normalized around 2 weeks.69 (C) Clinical studies showed 
evidence of BBB dysfunction reaching its max around 3-6 days after injury – depending on 
the type of insult and other factors – and returning to normal within several weeks.85 (D) 
However, there is evidence that BBB dysfunction can last for months to years and is 
















































































































































































































































































FIG. 4. The time course of axonal damage in rodents and humans measured by 
histopathology and in vivo imaging. (A) Following rotational acceleration injury in rats, APP 
histology showed rapid appearance of retraction bulbs and swollen axons in the corpus 
callosum, which gradually decreased and completely disappeared by day 14.108 (B) A 
similar time course was observed in mice after controlled cortical impact, but axonal 
varicosities were still detectable at 1 month post-injury using histology; diffusion tensor 
imaging also showed axonal abnormalities at the 1-month time point.112 (C) Human studies 
show a protracted APP histopathology with moderate to extensive axonal pathology up to 
1 year post-injury in 80% of cases investigated. (D) In fact, moderate axonal pathology was 
observed several years (up to 18) post-injury in 50% of clinical cases.129, 131  
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